Deutsch | English 

2016

 

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.https://www.ncbi.nlm.nih.gov/pubmed/27956157 Lancet Oncol. 2016 Dec 9. pii: S1470-2045(16)30632-5. doi: 10.1016/S1470-2045(16)30632-5.

 

Krowiorz K, Ruschmann J, Lai C, Ngom M, Maetzig T, Martins V, Scheffold A, Schneider E, Pochert N, Miller C, Palmqvist L, Staffas A, Mulaw M, Bohl SR, Buske C, Heuser M, Kraus J, O'Neill K, Hansen CL, Petriv OI, Kestler H, Döhner H, Bullinger L, Döhner K, Humphries RK, Rouhi A, Kuchenbauer F. MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia. Blood Cancer J. 2016 Dec 9;6(12):e508. doi: 10.1038/bcj.2016.110.

 

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016 Dec 7. doi: 10.1038/nature20598.

 

Buske C. Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia? Lancet Haematol. 2016 Nov 30. pii: S2352-3026(16)30163-6. doi: 10.1016/S2352-3026(16)30163-6.

 

Gentner E, Vegi NM, Mulaw MA, Mandal T, Bamezai S, Claus R, Tasdogan A, Quintanilla-Martinez L, Grunenberg A, Döhner K, Döhner H, Bullinger L, Haferlach T, Buske C, Rawat VP, Feuring-Buske M. VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice. Oncotarget. 2016 Nov 24. doi: 10.18632/oncotarget.13563.

 

Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C. Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus. Blood. 2016 Nov 8. pii: blood-2016-04-706978.

 

Bogen A, Buske C, Hiddemann W, Bohlander SK, Christ O. Variable aldehyde dehydrogenase activity and effects on chemosensitivity of primitive human leukemic cells. Exp Hematol. 2016 Nov 5. pii: S0301-472X(16)30695-6. doi: 10.1016/j.exphem.2016.10.012.

 

Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E; ESMO Lymphoma Consensus Conference Panel Members.. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol. 2016 Oct 4. pii: mdw419.

 

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee..appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies). Ann Oncol. 2016 Sep;27(suppl 5):v143-v144.

 

Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA. Treatment recommendations for Waldenström macroglobulinemia from the Eighth International Workshop on WM. Blood 2016 Jul 18. pii: blood-2016-04-711234.

  

Vegi NM, Klappacher J, Oswald F, Mulaw MA, Mandoli A, Thiel VN, Bamezai S, Feder K, Martens JH, Rawat VP, Mandal T, Quintanilla-Martinez L, Spiekermann K, Hiddemann W, Döhner K, Döhner H, Stunnenberg HG, Feuring-Buske M, Buske C. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML. Cell Rep. 2016 Jul 12;16(2):498-507.

 

Daria D, Kirsten N, Muranyi A, Mulaw M, Ihme S, Kechter A, Hollnagel M, Bullinger L, Döhner K, Döhner H, Feuring-Buske M, Buske C. GPR56 contributes to the development of acute myeloid leukemia in mice. Leukemia 2016 Aug;30(8):1734-41.

 

Daria D, Kirsten N, Muranyi A, Mulaw M, Ihme S, Kechter A, Bullinger L, Döhner K, Döhner H, Feuring-Buske M, Buske C. GPR56 contributes to the development of acute myeloid leukemia in mice. Leukemia 2016; Apr 11. doi: 10.1038/leu.2016.76.

 

Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C; ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol  2016; Apr 7. pii: mdw025.

 

 

Grunenberg A, Buske C. New developments in Waldenström's macroglobulinemia. Dtsch Med Wochenschr 2016; Feb;141(3):170-2. doi: 10.1055/s-0041-107960.

 

Schmid F, Schmid M, Müssel C, Sträng JE, Buske C, Bullinger L, Kraus JM, Kestler HA. GiANT: gene set uncertainty in enrichment analysis. Bioinformatics 2016; Feb 1. pii: btw030. 

 

Grunenberg A, Buske C. Waldenström's macroglobulinemia : Current developments in diagnostics and therapy. Internist (Berl) 2016; Mar;57(3):238-44. doi: 10.1007/s00108-015-0005-7.

 

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica 2016; Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739.

 

 

2015

 

 

Schneider D, Dühren-von Minden M, Alkhatib A, Setz C, van Bergen CA, Benkißer-Petersen M, Wilhelm I, Villringer S, Krysov S, Packham G, Zirlik K, Römer W, Buske C, Stevenson FK, Veelken H, Jumaa H. Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma. Blood 2015; 125(21): 3287-3296.

 

Hess G, Keller U, Scholz CW, Witzens-Harig M, Atta J, Buske C, Kirschey S, Ruckes C, Medler C, van Oordt C, Klapper W, Theobald M, Dreyling M. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Leukemia 2015; 29(8): 1695-1701.

 

Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, Heuser M, Hogge D, Camargo FD, Engelhardt S, Döhner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries RK, Kuchenbauer F. MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol 2015; pii: S0301-472X(15)00511-1.

 

Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, Thiele J, Buske C; ESMO Guidelines Committee. Philadelphia chromoseome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; Suppl. 5: V85-V99.

 

Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C; ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; Suppl. 5: v100-v107.

 

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C, ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; Suppl. 5: v78-v84.

 

Buske C, Seymour J. Immunochemotherapy in Waldenström macroglobulinemia - still the backbone of treatment. Leuk Lymphoma. 2015 Jun 9: 1-6.

 

Schneider V, Zhang L, Rojewski M, Fekete N, Schrezenmeier H, Erle A, Bullinger L, Hofmann s, Götz M, Döhner K, Ihme S, Döher H, Buske C, Feuring-Buske M, Greiner J. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. Int J Cancer 2015, Apr 24. doi: 10.1002/ijc.29583.

 

2014

 

 

Buske C. Towards a chemotherapy-free approach in indolent lymphoma. Lancet Oncol. 2014 Nov;15(12):1281-2.

 

Fenaux P, Haase D, Sanz GF, Santini V, Buske C; ESMO Guidelines Working Group. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii57-69. 

 

Edmaier KE, Stahnke K, Vegi N, Mulaw M, Ihme S, Scheffold A, Rudolph KL, Buske C. Expression of the lymphoid enhancer factor 1 (Lef-1) is required for normal hematopoietic stem and progenitor cell function. Leukemia. 2014 Jan;28(1):227-30. 

 

Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland MC, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD, Hoster E; Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia. J Clin Oncol. 2014 Apr 7.

 

CR Stadler, N Vegi, MA Mulaw, KE Edmaier, VPS Rawat, A Dolnik, L Bullinger, B Heilmeier, L Quintanilla-Fend, K Spiekermann, W Hiddemann, K Döhner, H Döhner, M Feuring-Buske, C Buske; The leukemogenicity of Hoxa9 depends on alternative splicing. Leukemia 2014  AMBER13-LEU-1614R

 

2013

 

Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M; ESMO Guidelines Working Group, Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi155-vi159.

 

Fey MF, Buske C; ESMO Guidelines Working Group. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi138-vi143.

 

Herold T, Mulaw MA, Jurinovic V, Seiler T, Metzeler KH, Dufour A, Schneider S, Kakadia PM, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Dreyling M, Bohlander SK. High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. Leuk Lymphoma. 2013 Aug;54(8):1652-7. 

 

Wu Y, Ihme S, Feuring-Buske M, Kuan SL, Eisele K, Lamla M, Wang Y, Buske C, Weil T. A Core-Shell Albumin Copolymer Nanotransporter for High Capacity Loading and Two-Step Release of Doxorubicin with Enhanced Anti-Leukemia Activity. Adv Healthc Mater. 2013 Jun;2(6):884-94. 

 

Chen L, Deshpande A, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Abrogation of MLL-AF10 and CALM-AF10 mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013 Apr;27(4):813-22. 

  

Buske C. & Leblond V. How I manage to treat Waldenstrom’s macroglobulinemia. Leukemia. 2013 Apr;27(4):762-72.

 

Grasedieck S, Sorrentino A, Langer C, Buske C, Döhner H, Mertens D, Kuchenbauer F. Circulating microRNAs in hematological diseases: principles, challenges and perspectives. Blood 2013 Jun 20;121(25):4977-84.

 

Diffner E, Beck D, Gudgin E, Thoms J, Knezevic K, Pridans C, Foster S, Goode D, Khong Lim W, Boelen L, Metzeler K, Micklem G, Bohlander S, Buske C, Burnett A, Ottersbach K, Vassiliou G, Olivier J, Wong J, Gottgens B, Huntly B, Pimanda JE. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukaemia. Blood. 2013 Mar 21;121(12):2289-300. 

 

2012

 

Langer C, Rücker FG, Buske C, Döhner H, Kuchenbauer F. Targeted therapies through microRNAs: pulp or fiction? Ther Adv Hematol. 2012 Apr;3(2):97-104.

 

Buske C, Herold M, Willenbacher W, Dreyling M. Follikuläres Lymphom. Onkopedia-DGHO, Mai 2012.

 

Bamezai S, Rawat VP, Buske C. The Piwi - piRNA Axis: Pivotal Beyond Transposon Silencing. Stem Cells. 2012, 12: 2603-2611.

 

Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M. Ann Hematol. 2012, 11: 1765-1772.

 

Metzeler KH, Heilmeier B, Edmaier KE, Rawat VPS, Dufour A, Doehner K, Feuring-Buske M, Braess J, Spiekermann K, Buchener T, Sauerland MC, Doehner H, Hiddemann W, Bohlander SK, Schlenk RF, Bullinger L, Buske C. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood 2012; 120 (10): 2118 - 2126.

 

Mulaw MA, Krause AJ, Deshpande AJ, Krause LF, Rouhi A, La Starza R, Borkhardt A, Buske C, Mecucci C, Ludwig WD, Lottaz C, Bohlander SK. CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12. Leukemia. 2012 May; 26(5): 1012 - 1019.

 

Mantelzell- Lymphom. Dreyling M, Herold M, Drach J, Rummel M, Buske C. Onkopedia-DGHO, März 2012.

 

Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Kakadia PM, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Hiddemann W, Spiekermann K. The FLT3ITD level has a high prognostic impact in NPM1 mutated, but not NPM1 unmutated AML with a normal karyotype. Blood. 2012 119: 4383-4386.

 

Rawat VP, Humphries RK, Buske C. Beyond HOX: the role of ParaHOX genes in normal and malignannt hematpoiesis. Blood. 2012 120(3): 519-527.

Grasedieck S, Schöler N, Bommer M, Niess JH, Tumani H, Rouhi A, Bloehdorn J, Liebisch P, Mertens D, Döhner H, Buske C, Langer C, Kuchenbauer F. Impact of serum storage conditions on microRNA stability. Leukemia. 2012, 26 (11): 2414-2416. 

 

Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Bergel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, Creutzig U, Thiede C, Zwaan MC, van den Heuvel-Eibrink MM, Reinhardt D, Hiddemann W, Spiekermann K. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal kariotype AML (NK-AML). Ann Hematol 2012; 91: 9-18.

 

Azimzadeh O, Scherthan H, Yentrapalli R, Barjaktarovic Z, Ueffing M, Conrad M, Neff F, Calzada-Wack J, Aubele M, Buske C, Atkinson MJ, Hauck SM, Tapio S. Label-free protein profiling of formalin fixed paraffin-embedded (FFPE) heart tissue reveals immediate mitochondrial impairment after ionising radiation. J Proteomics. 2012 Apr 18;75(8):2384-95.

 

2011

 

Mohr F, Döhner K, Buske C, et al. TET genes: New players in DNA demethylation and important determinants for stemness. Exp Hematol 2011; 39: 272-281.

 

Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Medicine 2011; 17: 1086-1093.

 

Kuchenbauer F, Mah SM, Heuser M, et al. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood 2011; 118(12): 3350-3358.

 

Rouhi A, Buske C. Stem cells and beyond: report on the 40th Annual Scientific Meeting of the International Society of Experimental Hematology. Expert Rev Hematol 2011; 4(6): 591-592.

 

Deshpande AJ, Rouhi A, Lin Y, et al. The clathrin binding domain of CALM and OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia 2011; 25(11): 1718-1727.

 

Azimzadeh O, Scherthan H, Sarioglu H, Barjaktarovic Z, Conrad M, Vogt A, Calzada-Wack J, Neff F, Aubele M, Buske C, Atkinson MJ, Tapio S. Rapid proteomic remodeling of cardiac tissue caused by total body ionizing radiation. J Proteomics 2011 11: 3299-3311.

 

Herold T, Jurinovic V, Mulaw M, et al. Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected experssion pattern of the RHO GTPase activator ARHGAP20.  Genes Chromosomes Center 2011; 50: 546-558.

 

Herold T, Jurinovic V, Metzeler KH, et al. An 8 gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 2011; 25: 1639-1645.

 

2010

 

Rawat VP, Arseni N, Ahmed F, et al. The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2010; 107(39): 16946-19851.

 

Buske C. Hematologic malignancies-sixth European congress. 26-28 February 2010, Cannes, France. Drugs 2010;13:300-303.

 

Buske C. Indolent lymphoma in the elderly. Proceedings of the first international conference on Haematological Malignancies in the Elderley. Lissabon, Portugal, 2010; 5: 67-68.

 

Mah SM, Buske C. Humphries RK, Kuchenbauer F. miRNA: A passenger stranded in RNA-induced silencing complex? Crit Rev Eukariot Gene Expr 2010; 20(2): 141-148. Review.

 

Schöler N, Langer C, Döhner H, Buske C, Kuchenbauer F. Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol 2010; 38(12): 1126-30. Review.

 

2009

 
Rao AV, Valk PJ, Metzeler KH, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol. 2009;27:5580-5586.


Deshpande A, Pastore A, Deshpande AJ, et al. 3'UTR mediated regulation of the cyclin D1 proto-oncogene. Cell Cycle. 2009;8:3584-3592.


Metzeler KH, Dufour A, Benthaus T, et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol. 2009;27:5031-5038.


Deshpande AJ, Ahmed F, Buske C. Identification of murine and human acute myeloid leukemia stem cells. Methods Mol Biol. 2009;568:21-35.


Heilmeier B, Spiekermann K, Bohlander S, et al. [Modern leukemia diagnosis in adults]. Dtsch Med Wochenschr. 2009;134:1222-1226.


Lin YH, Kakadia PM, Chen Y, et al. Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias. Blood. 2009;114:651-658.


Schneider F, Hoster E, Unterhalt M, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood. 2009;113:5250-5253.


Reindl C, Quentmeier H, Petropoulos K, et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res. 2009;15:2238-2247.


Thoene S, Rawat VP, Heilmeier B, et al. The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia. 2009;23:649-655.


Braess J, Spiekermann K, Staib P, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood. 2009;113:3903-3910.


Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23:153-161.

 

2008

 

Buske C, Gisselbrecht C, Gribben J, Letai T, McLaughlin P, Wilson W. Refining the treatment of follicular lymphoma. Leuk Lymphoma. 2008;49 Suppl 1:18-26.


Archangelo LF, Greif PA, Holzel M, et al. The CALM and CALM/AF10 interactor CATS is a marker for proliferation. Mol Oncol. 2008;2:356-367.


Metzeler KH, Hummel M, Bloomfield CD, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112:4193-4201.


Vempati S, Reindl C, Wolf U, et al. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. Clin Cancer Res. 2008;14:4437-4445.


Petropoulos K, Arseni N, Schessl C, et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med. 2008;205:515-522.


Ahmed F, Arseni N, Glimm H, Hiddemann W, Buske C, Feuring-Buske M. Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors. Stem Cells. 2008;26:810-818.


Rawat VP, Thoene S, Naidu VM, et al. Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia. Blood. 2008;111:309-319.

 

2007

 

Schmitz N, Buske C, Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Semin Hematol. 2007;44:234-245.


Deshpande AJ, Buske C. Knocking the Wnt out of the sails of leukemia stem cell development. Cell Stem Cell. 2007;1:597-598.


Buske C, Hiddemann W. [The older patient with malignant diseases]. Internist (Berl). 2007;48:1206,1208-1210.


Metzeler KH, Braess J, Spiekermann K, et al. [Fortuitous finding: thrombocytopenia and thrombocytosis]. MMW Fortschr Med. 2007;149:34-35, 37.


Schneider F, Bohlander SK, Schneider S, et al. AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. Leukemia. 2007;21:2199-2201.


Kohl TM, Hellinger C, Ahmed F, et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia. 2007;21:1763-1772.


Fritsch S, Buske C, Wormann B, Wedding U, Hiddemann W, Spiekermann K. [Therapy of acute myeloid leukemia (AML) for medically non-fit patients]. Med Klin (Munich). 2007;102:324-329.


Heilmeier B, Buske C, Spiekermann K, et al. [Diagnostics, classification and prognostic criteria of acute myeloid leukemia]. Med Klin (Munich). 2007;102:296-308.


Christ O, Feuring-Buske M, Hiddemann W, Buske C. [Pathobiology of acute myeloid leukemia]. Med Klin (Munich). 2007;102:290-295.


Buske C, Hiddemann W. [Malignant lymphoma--there are still many open questions]. Internist (Berl). 2007;48:349-350.


Deshpande AJ, Buske C. Lymphoid progenitors as candidate cancer stem cells in AML: new perspectives. Cell Cycle. 2007;6:543-545.


Buske C, Unterhalt M, Hiddeman W. [Therapy of follicular lymphoma]. Internist (Berl). 2007;48:372-381.


Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M. Current management of follicular lymphomas. Br J Haematol. 2007;136:191-202.

 

2006

 

Deshpande AJ, Cusan M, Rawat VP, et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell. 2006;10:363-374.


Fritsch S, Metzeler K, Hiddemann W, Buske C. [Diagnostics and therapy of acute myeloid leukemia]. Dtsch Med Wochenschr. 2006;131:2401-2406.


Kuchenbauer F, Schnittger S, Look T, et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol. 2006;134:616-619.


Weigert O, Dreyling M, Unterhalt M, Hiddemann W, Buske C. Investigational strategies in autologous stem cell transplantation for follicular lymphoma. Curr Oncol Rep. 2006;8:368-375.


Metzeler K, Fritsch S, Buske C, Hiddemann W. [Acute myeloid leukemia -- on the way towards pathogenesis-oriented treatment]. Dtsch Med Wochenschr. 2006;131:1466-1468.


Hiddemann W, Spiekermann K, Braess J, Feuring-Buske M, Buske C, Buchner T. [Risk-adapted therapy of acute myeloid leukemia]. Internist (Berl). 2006;47 Suppl 1:S33-39.


Buske C, Hiddemann W. Rituximab maintenance therapy in indolent NHL: a clinical review. Leuk Res. 2006;30 Suppl 1:S11-15.


Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504-1508.


Buske C, Glimm H, Feuring-Buske M. [Stem cell therapy. Biology of hematopoietic stem cells]. Internist (Berl). 2006;47:459-460, 462-454.


Buske C, Weigert O, Dreyling M, Unterhalt M, Hiddemann W. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica. 2006;91:104-112.


Feuring-Buske M, Hartmann EM, Ott G, Reuter H, Buske C, Rosenwald A. [DNA-chips in the diagnosis of hematological malignancies]. Internist (Berl). 2006;47:39-46.


2005

 

Kuchenbauer F, Feuring-Buske M, Buske C. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia. Cell Cycle. 2005;4:1716-1718.


Arseni N, Ahmed F, Hiddemann W, Buske C, Feuring-Buske M. Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells. Haematologica. 2005;90:1577-1578.


Hiddemann W, Spiekermann K, Buske C, et al. Towards a pathogenesis-oriented therapy of acute myeloid leukemia. Crit Rev Oncol Hematol. 2005;56:235-245.


Dreyling M, Buske C, Hiddemann W. [Up-to-date treatment of follicular lymphomas]. Dtsch Med Wochenschr. 2005;130:2149-2154.


Hiddemann W, Buske C, Dreyling M, et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol. 2005;23:6394-6399.


Schessl C, Rawat VP, Cusan M, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest. 2005;115:2159-2168.


Dreyling M, Buske C, Hiddemann W. Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma. Ann Oncol. 2005;16 Suppl 2:ii99-104.


Buske C, Dreyling M, Unterhalt M, Hiddemann W. Transplantation strategies for patients with follicular lymphoma. Curr Opin Hematol. 2005;12:266-272.


Buske C, Dreyling M, Unterhalt M, Hiddemann W. [Monoclonal antibody therapy for malignant lymphoma]. Med Klin (Munich). 2005;100:14-24. 


2004- 2000

 

Buske C, Dreyling M, Unterhalt M, Hiddemann W. [Monoclonal antibody treatment of malignant lymphoma]. Internist (Berl). 2004;45:1370-1377.


Buske C, Dreyling H, Unterhalt M, Hiddemann W. Novel treatment strategies in follicular lymphoma. Ann Hematol. 2004;83 Suppl 1:S72.


Rawat VP, Cusan M, Deshpande A, et al. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proc Natl Acad Sci U S A. 2004;101:817-822.


Pineault N, Buske C, Feuring-Buske M, et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood. 2003;101:4529-4538.


Spiekermann K, Dirschinger RJ, Schwab R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 2003;101:1494-1504.


Feuring-Buske M, Hiddemann W, Buske C. [Pathogenesis and biology of leukemias]. Internist (Berl). 2002;43:1179-1189.


Buske C, Hiddemann W. [Acute and chronic leukemias. Current aspects of pathogenesis, diagnosis and therapy]. Internist (Berl). 2002;43:1177-1178.


Buske C, Feuring-Buske M, Abramovich C, et al. Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood. 2002;100:862-868.


Blaschke S, Hannig H, Buske C, Kaup FJ, Hunsmann G, Bodemer W. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques. J Med Virol. 2001;65:114-120.


Buske C, Feuring-Buske M, Antonchuk J, et al. Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood. 2001;97:2286-2292.


Buske C, Humphries RK. Homeobox genes in leukemogenesis. Int J Hematol. 2000;71:301-308.

 

 

 

gepunktete blaue Linie 1000px breit